As increased dependence on the BCL-2 family has been linked to disease progression and TKI resistance, it was hypothesized that BH3 mimetics may be promising candidates for the treatment of TKI-resistant CML. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.